2017
FungiScope™—Global Emerging Fungal Infection Registry
SEIDEL, Danila; Luisa A. DURÁN GRAEFF; Maria J.G.T. VEHRESCHILD; Hilmar WISPLINGHOFF; Maren ZIEGLER et. al.Základní údaje
Originální název
FungiScope™—Global Emerging Fungal Infection Registry
Autoři
SEIDEL, Danila; Luisa A. DURÁN GRAEFF; Maria J.G.T. VEHRESCHILD; Hilmar WISPLINGHOFF; Maren ZIEGLER; Janne J. VEHRESCHILD; Blasius LISS; Axel HAMPRECHT; Philipp KÖHLER; Zdeněk RÁČIL; Nikolay KLIMKO; Donald C. SHEPPARD; Raoul HERBRECHT; Anuradha CHOWDHARY a Oliver A. CORNELY
Vydání
Mycoses, Hoboken, Wiley-Blackwell, 2017, 0933-7407
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30216 Dermatology and venereal diseases
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Impakt faktor
Impact factor: 2.793
Kód RIV
RIV/00216224:14110/17:00097250
Organizační jednotka
Lékařská fakulta
UT WoS
000406076600003
EID Scopus
2-s2.0-85024908436
Klíčová slova anglicky
fungal infection; global cooperation; immunocompromised; orphan disease; registry
Štítky
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 20. 3. 2018 13:57, Soňa Böhmová
Anotace
V originále
Rare invasive fungal diseases (IFD) are challenging for the treating physicians because of their unspecific clinical presentation, as well as the lack of standardised diagnostic and effective treatment strategies. Late onset of treatment and inappropriate medication is associated with high mortality, thus, urging the need for a better understanding of these diseases. The purpose of FungiScope™ is to continuously collect clinical information and specimens to improve the knowledge on epidemiology and eventually improve patient management of these orphan diseases. FungiScope™ was founded in 2003, and today, collaborators from 66 countries support the registry. So far, clinical data of 794 cases have been entered using a web-based approach. Within the growing network of experts, new collaborations developed, leading to several publications of comprehensive analyses of patient subgroups identified from the registry. Data extracted from FungiScope™ have also been used as the sole control group for the approval of a new antifungal drug. Due to the rarity of these diseases, a global registry is an appropriate method of pooling the scarce and scattered information. Joining efforts across medical specialities and geographical borders is key for researching rare IFD. Here, we describe the structure and management of the FungiScope™ registry.